Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level903 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04420130 | A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009） | withdrawn | N/A | 0 | Yanqiao ZhangOTHER | 0 | Oct 4, 2022 | clinicaltrials |
| NCT04632199 | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer. | withdrawn | Phase 1 | 0 | IpsenINDUSTRY | 2 | Aug 24, 2022 | clinicaltrials |
| NCT04306861 | Novel MRI Techniques for Pancreatic Cancer | withdrawn | — | 0 | Beth Israel Deaconess Medical CenterOTHER | 0 | Jul 21, 2022 | clinicaltrials |
| NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity | withdrawn | Early Phase 1 | 0 | University Hospitals Cleveland Medical CenterOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05212025 | Adavosertib and Gemcitabine in Advanced Pancreatic | withdrawn | Phase 2 | 0 | James Cleary, MD, PhDOTHER | 0 | Jun 14, 2022 | clinicaltrials |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT03117556 | Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer | withdrawn | N/A | 0 | University of LouisvilleOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma(PANC-001) | withdrawn | Phase 1 | 0 | Roger Williams Medical CenterOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer(CIPHER) | withdrawn | Phase 3 | 0 | University of Texas Southwestern Medical CenterOTHER | 2 | May 26, 2021 | clinicaltrials |
| NCT03358095 | Cancer of the Head of the Pancreas: Early Surgery or Preoperative Biliary Drainage? | withdrawn | N/A | 0 | Helsinki University Central HospitalOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT03350763 | Biliary Drainage Preceding Possible Pancreaticoduodenectomy. Are Self-expandable Metallic Stents (SEMS) Superior to Plastic Stents? | withdrawn | N/A | 0 | Helsinki University Central HospitalOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04083651 | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Bausch Health Americas, Inc.INDUSTRY | 1 | May 7, 2021 | clinicaltrials |
| NCT04151719 | An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | withdrawn | Phase 3 | 0 | Bausch Health Americas, Inc.INDUSTRY | 0 | May 7, 2021 | clinicaltrials |
| NCT03536208 | Biological Effect of Warfarin on Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT03649035 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | withdrawn | Phase 3 | 0 | Istituto Clinico HumanitasOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT03718650 | Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jan 15, 2021 | clinicaltrials |
| NCT04034745 | Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain | withdrawn | — | 0 | Andrew Hendifar, MDOTHER | 0 | Dec 30, 2020 | clinicaltrials |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT02919553 | Modified Wet Suction Versus Capillary Techniques for EUS Guided Fine Needle Aspiration and Biopsy of Solid Lesions | withdrawn | N/A | 0 | Loma Linda UniversityOTHER | 0 | Oct 20, 2020 | clinicaltrials |
| NCT03509298 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT03038477 | A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT00882765 | Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT01092689 | The Role of Meat-borne Carcinogens in Pancreatic Cancer | withdrawn | Phase 1 | 0 | University of MinnesotaOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT03891979 | Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma | withdrawn | Phase 4 | 0 | NYU Langone HealthOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT01524575 | Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 | withdrawn | Phase 2 | 0 | University of HawaiiOTHER | 1 | Sep 25, 2019 | clinicaltrials |
| NCT02449967 | HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02885727 | Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)(Panc-Durval+RT) | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 0 | Sep 12, 2019 | clinicaltrials |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B | withdrawn | Phase 1 / Phase 2 | 0 | Alan KatzOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02205788 | Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas | withdrawn | — | 0 | Patrick Joseph Loehrer Sr.OTHER | 0 | Jul 10, 2019 | clinicaltrials |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Hitendra PatelOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03797443 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Piedmont Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 30, 2019 | clinicaltrials |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03392571 | Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients | withdrawn | Phase 2 | 0 | Pancreatic Cancer Research TeamOTHER | 0 | May 7, 2019 | clinicaltrials |
| NCT02581501 | Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer | withdrawn | Phase 1 | 0 | Stamford HospitalOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT00968604 | C-VISA BikDD: Liposome in Advanced Pancreatic Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 11, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 4, 2022source: clinicaltrials